Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines

Biochemical Pharmacology

Volumn 75, Issue 10, 2008, Pages 1912-1923

  Ramos, Adrián M ^a   Aller, Patricio ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Apoptosis; Arsenic trioxide; GSH; Leukemia cells; Quercetin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARSENIC TRIOXIDE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BUTHIONINE SULFOXIMINE; CASPASE 8; CHRYSIN; CISPLATIN; CYTARABINE; CYTOCHROME C; GLUTATHIONE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN BID; PROTEIN BNIP3; PROTEIN KINASE B; QUERCETIN; SERINE PROTEINASE OMI; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; DRUG SYNERGISM; FLAVONOIDS; GLUTATHIONE; HUMANS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDES; PROTEIN KINASES; QUERCETIN;

EID: 42649083649     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.02.007     Document Type: Article

References (51)

1. Tallman M.S. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 20 (2007) 57-65
2. Larochette N., Decaudin D., Jacotot E., Brenner C., Marzo I., Susin S.A., et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 249 (1999) 413-421
3. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278 (2003) 37832-37839
4. Evens A.M., Tallman M.S., and Gartenhaus R.B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28 (2004) 891-900
5. Aggarwal B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71 (2006) 1397-1421
6. Nguyen T.T.T., Tran E., Do P.T., Huynh T.H., and Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25 (2004) 647-659
7. Kuo P.C., Liu H.F., and Chao J.I. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem 279 (2004) 55875-55885
8. Granado-Serrano A.B., Martín M.A., Bravo L., Goya L., and Ramos S. Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-Kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 136 (2006) 2715-2721
9. Lee T.J., Kim O.H., Kim Y.H., Lim J.H., Kim S., Park J.W., et al. Quercetin arrest G2/M phase and induces caspase-dependent cell death in U937 cells. Cancer Lett 240 (2006) 234-242
10. Yuan Z., Chen L., Fan L., Tang M., Yang G., Yang H., et al. Liposomal quercetin efficiently suppresses growth of solid tumours in murine models. Clin Cancer Res 12 (2006) 3193-3199
11. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., de Takats P.G., Anderson D., et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2 (1996) 659-668
12. Cipák L., Rauko P., Miadokavá E., Cipákova I., and Novotný L. Effects of flavonoids on cisplatin-induced apoptosis in HL-60 and L1210 leukemia cells. Leuk Res 27 (2003) 65-72
13. Jakuwovicz-Gil J., Paduch R., Piersiak T., Glowniak K., Gawron A., and Kandefer-Szerszen M. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol 69 (2005) 1343-1350
14. Sharma H., Sen S., and Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4 (2005) 949-955
15. Teofili L., Pierelli L., Iovino M.S., Leone G., Scambia G., De Vincenzo R., et al. The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leuk Res 16 (1992) 497-503
16. Dorta D.J., Pigoso A.A., Mingatto F.E., Rodrigues T., Prado I.M., Helena A.F., et al. The interaction of flavonoids with mitochondria: effects on energetic process. Chem Biol Interact 152 (2005) 67-78
17. Ishikawa Y., and Kitamura M. Anti-apoptotic effect of quercetin: intervention in the JNK- and ERK-mediated apoptotic pathways. Kidney Int 58 (2000) 1078-1087
18. Rubio S., Quintana J., Eiroa J.L., Triana J., and Estévez F. Acetyl derivative of quercetin 3-methyl ether-induced cell death in human leukaemia cells is amplified by the inhibition of ERK. Carcinogenesis 28 (2007) 2105-2113
19. Kachadourian R., and Day B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Rad Biol Med 41 (2006) 65-76
20. Cipák L., Bercezliová E., and Pauliková H. Effects of flavonoid on glutathione and glutathione-related enzymes in cisplatin-treated L1210 leukemia cells. Neoplasma 50 (2003) 443-446
21. Dai J., Weinberg R.S., Waxman S., and Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93 (1999) 268-277
22. Jing Y., Dai J., Chalmers-Redman R.E.M., Tatton W.G., and Waxman S. Arsenic trioxide selectively induces acute promyalocytic leukaemia cell apoptosis via hydrogen peroxide-dependent pathway. Blood 94 (1999) 2102-2111
23. Yang C.H., Kuo M.L., Chen J.C., and Chen Y.C. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81 (1999) 796-799
24. Grad J.M., Bahlis N.J., Reis I., Oshiro M.M., Dalton W.S., and Boise L.H. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98 (2001) 805-813
25. Ramos A.M., Fernández C., Amrán D., Sancho P., de Blas E., and Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105 (2005) 4013-4020
26. Ramos A.M., Fernández C., Amrán D., Esteban D., de Blas E., Palacios M.A., et al. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. J Cell Physiol 209 (2006) 1006-1015
27. Renvoize C., Roger R., Moulian N., Bertoglio J., and Bréard J. Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J Immunol 159 (1997) 126-134
28. Troyano A., Fernandez C., Sancho P., de Blas E., and Aller P. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J Biol Chem 276 (2001) 47107-47115
29. Bellosillo B., Villamor N., Lopez-Guillermo A., Marce S., Bosch F., Campo E., et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukaemia. Blood 100 (2002) 1810-1816
30. Fernández-Checa J.C., and Kaplowitz N. The use of monochloribimane to determine hepatic GSH levels and synthesis. Anal Biochem 190 (1990) 212-219
31. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapies. Oncogene 25 (2006) 4798-4811
32. Takayama S., Reed J.C., and Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 22 (2003) 9041-9047
33. Rong Y., Yang E.B., Zhang K., and Mack P. Quercetin-induced apoptosis in the monoblastoid cell line U937 in vitro and the regulation of heat-shock protein expression. Anticancer Res 20 (2000) 4339-4345
34. Amran D., Sánchez Y., Fernández C., Ramos A.M., de Blas E., Bréard J., et al. Arsenic trioxide sensitizes promonocytic leukemia cells to TNFα-induced apoptosis via p38-MAPK-regulated activation of both receptor-mediated and mitochondrial pathways. Biochem Biophys Acta 1773 (2007) 1653-1663
35. Fernández C., Ramos A.M., Sancho P., de Blas E., and Aller P. 12-O-Tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells. Regulation by extracellular signal-regulated protein kinases and glutathione. J Biol Chem 279 (2004) 3877-3884
36. 2-terminal kinase and up-regulation of death receptors. Cancer Res 66 (2006) 11416-11423
37. Nguyen T.T., Tran E., Nguyen T.H., Do P.T., Huynh T.H., and Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 cancer cells. Carcinogenesis 25 (2004) 647-659
38. Tabellini G., Tazzari P.L., Bortul R., Evangelisti C., Billi A.M., Grafone T., et al. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukemias. Br J Haematol 130 (2005) 716-725
39. Bailey H.H. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 111-112 (1998) 239-254
40. Candé C., Vahsen N., Métivier D., Tourrière H., Chebil K., Garrido C., et al. Regulation of cytoplasmic stress granules by apoptosis-inducing factor. J Cell Sci 117 (2004) 4461-4468
41. Scott N., Hatlelid K.M., MacKenzie N.E., and Carter D.E. Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem Res Toxicol 6 (1993) 102-106
42. Freund A., Boos J., Harkin S., Schultze-Mosgau M., Veerman G., Peters G.J., et al. Augmentation of 1-beta-d-arabinofuranosylcytosine (Ara-c) cytotoxicity in leukaemia cells by co-administration of antisignalling drugs. Eur J Cancer 34 (1998) 895-901
43. Yang Q.H., Church-Hajduk R., Ren J., Newton M.L., and Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev 17 (2003) 1487-1496
44. Demarchi F., and Brancolini C. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Resist Updat 8 (2005) 359-368
45. Aono J., Yanagawa T., Itoh K., Li B., Yoshida H., Kumagai Y., et al. Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. Biochem Biophys Res Commun 305 (2003) 271-277
46. Wieder T., Essmann F., Prokop A., Schmelz K., Schulze-Osthoff K., Beyaert R., et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97 (2001) 1378-1387
47. Akay C., and Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2 (2003) 358.368
48. Lo J.F., Wang H.F., Tam M.F., and Lee T.C. Glutathione S-transferase pi in an arsenic-resistant Chinese hamster ovary cell line. Biochem J 288 (1992) 977-982
49. Zhang X., Yang F., Shim J.Y., Kirk K.L., Anderson D.E., and Chen X. Identification of arsenic-binding proteins in human breast cancer cells. Cancer Let 255 (2007) 95-106
50. Vernhet L., Séité M.P., Allain N., Guillouzo A., and Fardel O. Arsenic induces expression of the multidrug resistance-associated protein 2 (MRP2) gene in primary rat and human hepatocytes. J Pharmacol Exp Ther 298 (2001) 234-239
51. Bozko P., Sabisz M., Larsen A.K., and Skladanowski A. Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications. Mol Cancer Ther 4 (2005) 2016-2025